Preclinical Animal Models to Power Up Psychiatric Drug Development

Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development.

Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat various psychiatric disorders such as depression, anxiety, schizophrenia, and others. The process of antipsychiatric drug development typically involves several stages, including identifying potential drug targets, conducting preclinical research to test the safety and efficacy of potential drug candidates, and then moving on to clinical trials to further evaluate the drug’s effectiveness and safety in human subjects. Animal models and cellular models are commonly used in preclinical research for psychiatric drug development as they help study the behavioral and physiological effects of potential drug candidates, as well as investigate the underlying mechanisms of psychiatric disorders.

With extensive experience in the antipsychiatry industry, the Ace Therapeutics Psychiatry team understands the unique challenges and complexities of developing effective therapies for psychiatric disorders. By leveraging its expertise and resources, the company can develop animal models, cell models, multicellular models, pharmacokinetic/pharmacodynamic modeling, biomarker discovery, and more. These model development services are designed to offer researchers the tools and resources they need to optimize drug development and maximize success rates.

So far, Ace Therapeutics has established various animal models of mental illness through methods such as selective breeding, genetic engineering, brain injury, and environmental manipulation.  Moreover, the company can also provide cellular models from high-quality sources for psychiatric pathology and drug discovery to enable researchers to study and model clinically important psychiatric disorders in relevant genetic and cellular environments.

The field of psychiatric drug development is constantly evolving, and Ace Therapeutics is committed to staying at the forefront of innovation. In addition to mental illness models, Ace Therapeutics can also provide drug development services including antipsychotics screening services, pharmacokinetics analysis services, lead discovery and optimization services to help researchers dive deeper into psychiatry research and drug development. These services will enable researchers to explore new pathways, identify potential drug targets, and ultimately bring life-changing treatments to patients in need.